Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor γ ligands

Journal of Pharmacology and Experimental Therapeutics

Volumn 311, Issue 2, 2004, Pages 467-475

  Rival, Yves ^a   Stennevin, Aline ^a   Puech, Laurence ^a   Rouquette, Anne ^a   Cathala, Claudie ^a   Lestienne, Fabrice ^a   Dupont Passelaigue, Elisabeth ^a   Patoiseau, Jean François ^a   Wurch, Thierry ^a   Junquéro, Didier ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [2 [3 (2,4 DIFLUOROPHENYL) 1 HEPTYLUREIDO]ETHYL]PHENOXY] 2 METHYLBUTYRIC ACID; 2,2 DICHLORO 12 (4 CHLOROPHENYL)DODECANOIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXYL]PHENOXY]ACETIC ACID; [4 [5 [2 [BIS(PHENYLMETHYL)AMINO] 2 OXOETHYL] 2 HEPTYL 4 OXO 3 THIAZOLIDINYL]BUTYL]BENZOIC ACID; DICLOFENAC; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 2; FATTY ACID BINDING PROTEIN 4; FENOFIBRATE; GALACTOSIDASE; GALACTOSIDASE 4; GW 0072; GW 2331; INDOMETACIN; LIGAND; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; AP2 GENE; ARTICLE; CARBOHYDRATE METABOLISM; CATABOLISM; CELL DIFFERENTIATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG MECHANISM; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN SENSITIVITY; LIGAND BINDING; LIPID STORAGE; LIPOGENESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; TIME; WEIGHT GAIN;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; BASE SEQUENCE; BUTYRATES; CARRIER PROTEINS; CLONING, MOLECULAR; COS CELLS; DNA; FATTY ACID-BINDING PROTEINS; GENES, REPORTER; HUMANS; MICE; PHENYLUREA COMPOUNDS; PPAR GAMMA; PROMOTER REGIONS (GENETICS); THIAZOLES; THIAZOLIDINES;

EID: 6344219500     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.068254     Document Type: Article

References (36)

1. Adamson DJ, Frew D, Tatoud R, Wolf CR, and Palmer CN (2002) Diclofenac antagonizes peroxisome proliferator-activated receptor-γ signaling. Mol Pharmacol 61: 7-12.
2. Aleo MD, Lundeen GR, Blackwell DK, Smith WM, Coleman GL, Stadnicki SW, and Kluve WM (2003) Mechanism and implications of brown adipose tissue proliferation in rats and monkeys treated with the thiazolidinedione darglitazone, a potent peroxisome proliferator-activated receptor-γ agonist. J Pharmacol Exp Ther 305: 1173-1182.
3. Barbier O, Torra P, Duguay Y, Blanquart C, Fruchart JC, Glineur C, and Staels B (2002) Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22:717-726.
4. Baxa CA, Sha RS, Buelt MK, Smith AJ, Matarese V, Chinander LL, Boundy KL, and Bernlohr DA (1989) Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA. Biochemistry 28:8683-8690.
5. Beckman J, Raji A, and Plutzky J (2003) Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities. Curr Opin Cardiol 6:479-485.
6. Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, et al. (2003) Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator. Mol Endocrinol 17:662-676.
7. Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, Shen XQ, Vanbogelen R, and Leff T (2000) Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone. Diabetes 49:539-547.
8. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, et al. (2001) A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161-171.
9. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Pineda Torra I, Teissier E, Minnich A, Jaye M, Duverger N, et al. (2001) PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of ABCA1 pathway. Nat Med 7:53-58.
10. Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz M, Moller DE, and Berger J (1996) Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun 224:431-437.
11. Graves RA, Tontonoz P, Platt KA, Ross SR, and Spiegelman BM (1992) Identification of a fat cell enhancer: analysis of requirements for adipose tissue-specific gene expression. J Cell Biochem 49:219-224.
12. Haffner S and Taegtmeyer H (2003) Epidemic obesity and the metabolic syndrome. Circulation 108:1541-1545.
13. Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington WW Jr, Hashim MA, Hull-Ryde EA, Kaldor I, et al. (1998) N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 41:5020-5036.
14. Heuckeroth RO, Birkenmeier EH, Levin MS, and Gordon JI (1987) Analysis of the tissue-specific expression, developmental regulation and linkage relationships of a rodent gene encoding heart fatty binding protein. J Biol Chem 262:9709-9717.
15. Kersten S, Desvergne B, and Wahli W (2000) Roles of PPARs in health and disease. Nature (Lond) 405:421-424.
16. Kishida K, Shimomura I, Nishizawa H, Maeda N, Kuriyama H, Kondo H, Matsuda M, Nagaretani H, Ouchi N, Hotta K, et al. (2001) Enhancement of the aquaporin adipose gene expression by a peroxisome proliferator-activated receptor γ. J Biol Chem 276:48572-48579.
17. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, and Kliewer SA (1997) Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272:3406-3410.
18. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, and Kliewer S (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956.
19. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, et al. (2001) PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099.
20. Mueller E, Drori S, Aiyer A, Yie J, Sarraf P, Chen H, Hauser S, Rosen ED, Ge K, Eoeder RG, and Spiegelman BM (2002) Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor γ isoforms. J Biol Chem 277:41925-41930.
21. Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr CP, Blanchard SG, et al. (1999) A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 96:6102-6106.
22. Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, et al. (2001) A selective peroxisome proliferator-activated receptor S agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306-5311.
23. Phillips M, Djian P, and Green H (1986) The nucleotide sequence of three genes participating in the adipose differentiation of 3T3 cells. J Biol Chem 261:10821-10827.
24. Prinsen CF, De Bruijn DR, Merkx GF, and Veerkamp JH (1997) Assignment of the human adipocyte fatty acid-binding protein gene (FABP4) to chromosome 8q21 using somatic cell hybrid and fluorescence in situ hybridization techniques. Genomics 40:207-209.
25. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, and Lazar MA (1998) A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. J Biol Chem 273:32679-32684.
26. Reginato MJ and Lazar MA (1999) Mechanisms by which thiazolidinediones enhance insulin action. Trends Endocrinol Metab 10:9-13.
27. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, and Camp HS (2002) PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgammal reactivates adipogenesis. Genes Dev 16:27-32.
28. Schöfl C and Lübben G (2003) Postmarketing surveillance study of the efficacy and tolerability of pioglitazone in insulin-resistant patients with type 2 diabetes mellitus in general practice. Clin Drug Investig 11:725-734.
29. Wahli W (2002) Peroxisome proliferator-activated receptors (PPARs): from metabolic control to epidermal wound healing. Swiss Med Wkly 132:83-91.
30. Wang YX, Lee CH, Tiep S, Yu TY, Ham J, Kang H, and Evans RM (2003) Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113:159-170.
31. Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver WR Jr, Willson TM, Kliewer SA, and Hotamisligil GS (2001) Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor γ agonists. J Biol Chem 276:25651-25653.
32. Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ, and Flier JS (1997) Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. J Biol Chem 272:20230-20235.
33. Willson TM, Brown PJ, Sternbach DD, and Henke BR (2000) The PPARs: from orphan receptors to drug discovery. 43:527-550.
34. Wilson PWF and Grundy SM (2003) The metabolic syndrome. Circulation 108:1537-1540.
35. Wurch T, Junquero D, Delhon A, and Pauwels PJ (2002) Pharmacological analysis of wild-type α, γ and δ subtypes of the human peroxisome proliferator-activated receptor. Naunyn-Schmiedeberg's Arch Pharmacol 365:133-140.
36. Yang B, Clifton LG, McNulty JA, Chen L, Brown KK, and Baer PG (2003) Effects of a PPARγ agonist, GI262570, on renal filtration fraction and nitric oxide level in conscious rats. J Cardiovasc Pharmacol 42:436-441.